In FVB mice, DEN-treated AR-overexpressing mice (TG2/FVB, TG1/FVB) had significantly higher tumor incidence (% mice with tumors > 1 μm), visible tumor number per mouse, maximal tumor size and accumulated tumor size (in diameter, mm) than the DEN-treated control mice (WT/FVB) (Figure 5), but not in body or liver weight (Supplementary Figure 5). The gene discussed is AR; the disease is neoplasm.